Gan & Lee Pharmaceuticals. (603087.SS)
| Previous close | 47.83 |
| Open | 47.82 |
| Bid | 48.97 x N/A |
| Ask | 48.98 x N/A |
| Day's range | 46.80 - 49.90 |
| 52-week range | 32.10 - 62.90 |
| Volume | |
| Avg. volume | 10,465,047 |
| Market cap | 29.441B |
| Beta (5Y monthly) | 1.61 |
| PE ratio (TTM) | 73.09 |
| EPS (TTM) | 0.67 |
| Earnings date | N/A |
| Forward dividend & yield | 0.20 (0.42%) |
| Ex-dividend date | 18 June 2024 |
| 1y target est | 63.00 |
PR NewswireGan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the results of the Phase 1b/2a clinical study of the Company's independently developed glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins' preclinical studies in poster presentations at the American Diabetes Association's（ADA's）84th Scientific Sessions.
PR NewswireGan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) announced today the presentation of three abstracts featuring their investigational products at the American Diabetes Association's (ADA's[1]) 84th Scientific Sessions. The meeting will be held in-person and virtually from June 21-24, 2024, in Orlando, Florida .
